检索结果 - Francesco Mazziotta
- Showing 1 - 2 results of 2
-
1
Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia 由 Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Benjamin Dickins, Heidi Altmann, Michael Krämer, Hanna A. Knaus, Bruce R. Blazar, Vedran Radojčić, Joshua F. Zeidner, Andrea Arruda, Bofei Wang, Hussein A. Abbas, Mark D. Minden, Sarah K. Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik
出版 2022Artigo -
2
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia 由 Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon, Alec Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo
出版 2021Artigo
相关主题
Immune checkpoint
Immunotherapy
Internal medicine
Medicine
Myeloid leukemia
Oncology
Astrobiology
Biology
Blockade
CD8
Cancer
Cancer research
Chemotherapy
Chemotherapy regimen
Cytarabine
Effector
Immune system
Immunology
Leukemia
Mitoxantrone
Pembrolizumab
Receptor
Refractory (planetary science)
Regimen